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1. Introduction 
The Fibronectin Type III domain (FN3) is a small globular protein domain of 90-100 amino 
acids found in thousands of proteins, over all of protein sequence space from bacteria to 
humans. In fact, sequence analysis estimates that the FN3 domain can be found in 
approximately 2% of all animal proteins (Bork & Doolittle, 1992). The frequency that these 
domains are found is even greater when considering the larger family, the Ig-like fold, of 
which FN3 is a specific member. Despite weak to no sequence identity and greatly divergent 
functions, FN3 domains fold into a common structure. Over 230 structures of FN3 domains 
have been deposited to the PDB database as of 2011 (> 990 when considering all Ig-like 
domains), showing that the fold consists of 7 antiparallel -strands that pack into two ┚-
sheets (Main et al., 1992) (Figure 1). These ┚-strands are designated with the nomenclature 
A-F with the loops connecting each strand designated by the strands it connects (For 
example, the AB loop connects strands A and B). With a few exceptions, structural 
variability of these domains is found exclusively in the loops connecting the -strands while 
the strands remain structurally conserved.  
The small size, simple structure, and robust prokaryotic expression levels of many FN3 
domains has led to the development of these proteins as important tools for the 
understanding of protein folding and stability. To date, two members of the FN3 family, the 
tenth FN3 domain from human Fibronectin (FnFN10) and the 3rd FN3 domain from human 
Tenascin-C (TnFN3) have been the most widely studied. Despite low levels of sequence 
identity (23%), these two FN3 domains fold into very similar structures with the majority of 
structural deviations occurring in the loops connecting the ┚-strands (Leahy et al., 1992, 
Main, et al., 1992). Of great importance to the use of FN3 domains in novel applications is 
the ability of proteins with very diverse sequences to fold into a common structure, thus 
allowing for these domains to be heavily mutated in order to incur a desired function. This 
property has been demonstrated in a series of experiments published from the Clarke lab in 
which a “fold approach” was taken to characterize the folding and stability of a number of 
FN3 and Ig domains. The resulting work has lead to the proposal that proteins of the FN3 
and related families fold by similar mechanisms involving nucleation from the B, C, E and F 
strands, even when no sequence similarity is detectable (Clarke et al., 1999, Hamill et al., 
2000a, Hamill et al., 2000b). Despite such similar structures and folding pathways, FN3 
domains can exhibit markedly different conformational stabilities. For example, the FnFN10 
and TnFN3 domains have conformational stabilities of 9.4 and 6.7 kcal mol-1 respectively 
and FnFN9, which resides directly adjacent to FnFN10 in the Fibronectin protein is 
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approximately 5-fold less stable than FnFN10 (Clarke et al., 1997, Cota & Clarke, 2000, Hamill 
et al., 1998, Plaxco et al., 1997). Understanding the causes of these differences is important for 
producing FN3 domains for pharmaceutical or industrial applications. One explanation for the 
high stability of FnFn10 may be the rapid rate at which this isolated domain folds, despite the 
presence of 8 proline residues that might be expected to slow down folding due to cis-trans 
isomerization (Plaxco et al., 1996, Plaxco, et al., 1997). Indeed the data available so far for FN3 
domains supports the hypothesis that the refolding rates of ┚-sheet proteins reflect overall 
stability (Finkelstein, 1991). Another contribution to the differences in conformational stability 
of these proteins may be differences in structural plasticity. NMR spectroscopy was used to 
determine that the side-chains in the hydrophobic core of TnFN3 had a higher degree of 
mobility than those of FnFN10, while mutational analysis has shown that FnFN10 is more 
amenable to surface mutation due to greater flexibility in peripheral regions of the protein 
(Best et al., 2004, Cota et al., 2000). In support of this model, Billings and colleagues produced a 
chimera of FnFN10 and TnFN3 which was composed of the hydrophobic core of TnFN3 and 
the surface and loops of FnFN10. This chimeric FN3 domain showed greater stability than that 
of TnFN3, suggesting that the surface composition and loops can significantly contribute to 
stability (Billings et al., 2008).  
 
Fig. 1. Solution structure of FN3 domain FnFN10 (PDB 1TTF). Labels indicate the identity of 
loop regions as well as the N and C-termini. 
The contributions of surface residues to FN3 stability and the ability of such residues to 
tolerate mutation are keys to the development of these domains for biotechnology 
applications in which various surfaces or loops are mutated to employ a new function (see 
below). This property was first exploited by Koide et al. who demonstrated that the surface 
exposed loops of FnFN10 could be randomized and used to select FN3 domains that interact 
with a novel ligand, ubiquitin, thereby imparting a non-natural function to the FN3 domain 
(Koide et al., 1998). Importantly, the authors were able to confirm that the FN3 domains 
produced with such foreign loops were able to maintain the overall FN3 structure, although 
the resulting binders had reduced conformational stability compared to that of FnFN10. 
Numerous subsequent biochemical and biotechnological applications of FN3 domains are 
described in this chapter. The success of these techniques is strongly dependent upon the 
ability of highly diverse FN3 domains to fold into a common structure while tolerating a 
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high level of sequence mutation. In the next section, selection systems which have been used 
to select FN3 domains of novel function are described, followed by descriptions of protein 
engineering studies designed to increase the overall stability of the FN3 scaffold and to 
evolve FN3 scaffolds with high affinity and selectivity for a particular target. Finally, a 
report of novel applications of engineered FN3 domains is provided. 
2. Selection technologies 
Over the last twenty years, a variety of display technologies have evolved as tools for 
protein engineering and selection of binding ligands. Such techniques can be broadly 
separated into phage display, in vitro display (including ribosome display, mRNA display, 
and DNA display) and yeast display strategies (Figure 2). Phage display requires 
propogation and secretion from bacteria (ie. E. coli) using prokaryotic secretion machinery 
while yeast display relies on the growth and secretion properties of eukaryotic yeast. In 
contrast, the in vitro display technologies are accomplished completely in vitro which allows 
for significant manipulation of the selection conditions and much larger libraries. 
 
Fig. 2. Display platforms used for engineering and selection of FN3 domains. A) Phage 
display using a phagemid vector where the FN3 domain is fused to the C-terminal domain 
of M13 pIII. The signal sequence used to direct secretion is the DsbA sequence. B) Yeast 
display platform involving fusion of the FN3 domain to the yeast cell membrane protein 
Aga2p. Aga2p associates with membrane bound Aga1 via disulfide linkages. C) mRNA 
display involving an RNA/DNA hybrid wherein the RNA encodes the FN3 domain; the 
ribosome is depicted with the 2 shaded ovals with the transcribed protein illustrated by the 
hollow circles. Puromycin is depicted with a solid oval with the linkage site to the nascent 
protein strand shown by a dotted arrow.  
Koide and coworkers first demonstrated the utility of the FN3 domain as a scaffold suitable 
for creation of libraries of variants (Koide, et al., 1998). Based on analysis of FN3 domains 
involved in protein interaction motifs that suggested loop residues were frequently involved 
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in binding, a library containing randomized sequences in the FG and BC loops was 
designed. The FN3 scaffold library was fused to the C-terminal fragment of pIII using a 
phagemid vector and pIII display was achieved by infection with helper phage. Following 
five rounds of selection, a ubiquitin specific binder with approximately M affinity for 
ubiquitin was isolated. Despite reduced stability and solubility compared to the native 
parental FN3 domain from fibronectin, this study set the groundwork for future studies 
expanding the applications of FN3 domains to therapeutic proteins. Richards and coworkers 
in the Koide lab subsequently demonstrated display and selection of FN3 domains on pVIII 
using a phagemid display vector (Julie Richards et al., 2003). Because of the relatively low 
affinity of the parent FnFN10 domain for integrin binding, multivalent pVIII display was 
used to identify a high affinity, selective binder to v3. The selected FN3 domain inhibits 
v3 dependent processes in vitro in a manner similar to that described for antibodies 
thereby providing additional support for the utility of FN3 scaffolds as antibody-mimetics.  
In 2006, Steiner and coworkers reported that highly stable, highly expressed proteins often 
demonstrate compromised display from standard phage display vectors (Steiner et al., 
2006). For filamentous phages, translated proteins need to traverse the bacterial wall to the 
periplasm before assembling into the mature phage particle. Transolocation is triggered by 
the signal sequences that precede the mature gene sequence and most standard phage 
display vectors rely on Sec-dependent translocation sequences (ie. OmpA).  Steiner et al. 
showed that exchange of the phage-fusion protein Sec-dependent signal sequence to the 
cotranslational signal recognition particle (SRP) translocation pathway enabled display 
improvements of up to 1000-fold. As illustrated in Figure 2A, Koide and coworkers applied 
this strategy to develop an improved phage display vector employing the DsbA signal 
sequence instead of the OmpA sequence used in earlier work. (Koide et al., 2007)  
In vitro display strategies have proved to be a valuable tool for selection of high affinity 
scFvs, protease resistant peptides, and other scaffold protein libraries (Binz et al., 2005, 
Eldridge et al., 2009, Hanes & Pluckthun, 1997). Xu and coworkers applied a novel mRNA 
display strategy to construct a library based on the structural analogy between FN3 domains 
and antibody V-domains (Xu et al., 2002). The library encoded 21 random residues in the 
BC, DE, and FG loops of the FnFN10 domain with a theoretical diversity of 2021. While one 
advantage of in vitro display libraries is the size of libraries it is possible to generate, the 
practical size of such libraries is ~1012. The Xu library was constructed in multiple pieces 
using PCR and random oligonucleotides to introduce diversity in to the loop regions. To 
remove non-productive sequences from the library, each segment was fused in frame to a T7 
promoter and amino and carboxy terminal tags and the translated product subjected to 
affinity purification on the appropriate affinity tag ligands. Productive library members 
were recovered by PCR and joined to prepare the full length library. For mRNA display, a 
library of dsDNA is transcribed to generate mRNA which is ligated to a puromycin 
containing oligonucleotide (Takahashi, 2003)(Figure 2B). An in vitro translation reaction is 
performed to yield the RNA/DNA/protein complex that can be selected for binding. The 
final step in the selection cycle is to recover the mRNA-protein complexes by PCR to 
regenerate an enriched dsDNA library. Xu et al. selected high affinity, highly selective 
inhibitors to TNF thereby confirming that the FnFN10 scaffold had broad utility for protein 
therapeutics and diagnostics applications. Reports from the Roberts lab have described 
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mRNA display selections for FN3 binders in a variety of applications involving both 
intracellular and extracellular targets (Liao et al., 2009, Olson & Roberts, 2007). 
Odegrip and coworkers have described the optimization of an in vitro display system that 
addresses the RNA instability challenges seen with mRNA and ribosome display (Odegrip 
et al., 2004). The method, termed CIS display, makes use of the property of the DNA 
replication initiator protein (RepA) to bind exclusively to the DNA from which it has been 
expressed (ie. in cis). Recently, Jacobs and coworkers have applied CIS display for 
identification of stable, high affinity binders from a consensus sequence based on FN3 
domains from human tenascin C (manuscript in preparation).  
One of the limitations of phage display systems is their reliance on bacterial expression. 
Wittrup and coworkers have exploited the eukaryotic secretion machinery in yeast to 
develop a display platform that can be screened to discriminate between domains of 
different stability and different affinity (Shusta et al., 1999) (Figure 2C). One advantage of 
yeast display is the ability to use fluorescence activated cell sorting (FACS) to sort specific 
clones on the basis of scaffold display level and binding activity. Yeast display has the 
disadvantage of limiting library diversity to ~108 due to the much lower transformation 
efficiency of yeast compared to bacteria. Despite the limitations on library size dictated by 
yeast, the studies by Lipovsek et al. demonstrate the utility of yeast display for maturation 
of high affinity binders (Lipovsek et al., 2007). Randomizing only two loops (14 residues) of 
the 10Fn3 domain and using libraries several orders of magnitude smaller than those 
possible with mRNA display, Lipovsek was able to select binders to TNF with sub-
nanomolar affinity, a 340-fold improvement from the parental clone.  Hackel and coworkers 
have extended the application of yeast display with more complex library designs building 
on the basic principle of improved display correlating with improved stability. Using FACS 
to sort clones on the basis of display level and binding activity together with a step-wise 
affinity maturation scheme that relies on the yeast homologous recombination machinery 
for in vivo shuffling, stable, high affinity binders to a variety of targets were identified 
(Hackel et al., 2010, Hackel et al., 2008a).  
3. Engineering for stability and solubility 
One of the significant advantages of alternative scaffolds compared to antibodies is the 
improved biophysical properties for scaffold domains. Indeed, the stability and solubility 
properties of FN3 domains are an important point of differentiation that may allow for 
increased tissue penetration, reduced immunogenicity, and development of high 
concentration formulations. Often, sequence modifications to very small stable protein 
domains can have a significant impact on protein stability and solubility. Thus, researchers 
working on protein scaffolds have developed strategies to maximize and screen for domain 
stability as part of the selection process.  
As the originators of the FN3 scaffold design work, Koide and coworkers were early leaders 
in exploring domain stability. In contrast to the generally accepted premise that surface 
electrostatic interactions have little role in overall protein stability, the studies by Koide 
demonstrate that a negatively charged patch on the surface of FnFN10 plays an important 
role in limiting the stability of the domain (Koide et al., 2001). Mutation of one of the 
negatively charged residues to a neutral asparagine residue or to a positively charged lysine 
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residue increased the Tm for the proteins by 7° or 9°C compared to the native domain.  These 
studies suggest the potential for improved stability of selected FnFN10 domains by 
engineering surface residues.  
As researchers began to consider introduction of diversity into a variety of alternative 
scaffold domains to enable selection of novel therapeutic and diagnostic candidates, Batori 
and coworkers systematically explored the effects of loop elongation on each of the loops in 
FnFN10 (Batori et al., 2002). In order to determine which loops of the domain might be best 
utilized for target binding, they assessed the impact of elongation on the conformational 
stability of the domain. While it was possible to introduce up to four additional glycine 
residues in all six loops of FnFN10 while retaining the global fold, EF loop elongation was 
highly destabilizing. Mutations in the other five loops had only modest destabilizing effects 
suggesting the potential to use the loops for engineering binding affinity.  
Dutta et al. explored the potential to apply yeast two-hybrid fragment complementation to 
select FN3 domains with improved stability (Dutta et al., 2005). To assess complementation, 
FN3 fragment pairs were designed wherein the C-terminal fragment of each pair was fused to 
the LexA DNA binding domain and the N-terminal fragment was fused to the B42 activation 
domain. A yeast two-hybrid -galactosidase assay was used to evaluate each of the 
combinations for the ability to regenerate a highly stable domain. The scientists hypothesized 
that an increase in the affinity of fragment complementation would increase the stability of the 
uncut parental protein. Using three previously identified destabilizing mutations, a library of 
mutants was designed with the intent to select for compensating mutations in the opposite 
fragment. Mutations obtained from the selection re-introduced into the wild type and mutant 
domains resulted in ~2 kcal/mol increase in stability and demonstrated the utility of the 
fragment complementation method for identification of stabilizing mutations.  
Stability and solubility properties of candidate therapeutics are of key importance for 
successful development. From a chemistry, manufacturing and controls (CMC) perspective, 
the stability properties of a biotherapeutic candidate often play a major role in the design of 
purification strategies, protease sensitivity and storage conditions. For example, an early 
step in the purification of bacterially expressed FN3 domains with a high melting 
temperature can involve heating the bacterial lysate to > 60°C where most host proteins 
unfold irreversibly. The FN3 domain remains in solution and significant purification is 
achieved. For storage of final product, high stability products offer the potential advantage 
of room temperature storage. Parker and coworkers (Parker et al., 2005) reported on a 
strategy to improve the thermal stability of selected FN3 domains. In previous experiments, 
two anti-VEGF-R2 binding clones were identified with only six amino acid differences 
between sequences. Nevertheless, there were significant differences in the biophysical 
properties of the clones. Clone VR28 had a relatively low affinity of 13 nM for VEGR2 and 
relatively higher thermal stability of 62°C while clone 159 was higher affinity with a Kd of 
0.34 nM for VEGF-R2 and a thermal stability of 32-52°C. In addition, the two clones exhibit 
significant differences in solubility and aggregation state. Examination of the sequences for 
the wt and two FnFN3 derivatives enabled design of mutants with high affinity (0.59 nM) 
and high thermal stability (59°C).   
Olson and Roberts took a novel approach to identifying FN3 domain variants with good 
stability and solubility properties using a green fluorescent protein (GFP) reporter screen 
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(Garcia-Ibilcieta et al., 2008), SDS-PAGE analysis and chemical denaturation (Olson & 
Roberts, 2007). A library comprising 7 random residues in the BC loop and 10 random 
residues in the FG loop was synthesized by overlap PCR and inserted in frame between a T7 
promoter and a tobacco mosaic virus translation enhancer for mRNA display. The library 
was also cloned into a GFP fusion vector for assessment of library quality (ie. in frame 
sequences, no stop codons) and folding. Approximately 45% of the library sequences 
appeared to be in frame with no stop codons. Given the large size of the library (> 1013 
sequences), the functional size remains significantly larger than is possible with other 
display methods. Overall fluorescence intensities of “functional” clones populated a 
continuum of fluorescence values from <1%-130% of the parental domain standard. 
Approximately 20% of the library had fluorescence values between 80%-130%, suggesting 
that these variants are well folded with an additional 30% of the library exhibiting 
fluorescence values consistent with potential utility. This study demonstrates the value of 
GFP screening to evaluate complex FN3 domain libraries for library quality and 
maintenance of proper folding.  
Olson and coworkers applied the GFP screening strategy for identification of FN3 scaffold 
IkBa binders with improved solubility (Olson et al., 2008). Three rounds of evolution using 
error-prone PCR on a low solubility binder were performed. Following each round of 
evolution, approximately 2000 colonies were screened for increased fluorescence using the 
GFP fusion technology described above. By combining two point mutations correlated with 
improved solubility, Olson was able identify an FN3 clone with expression improved to ~ 
1mg/L culture while maintaining affinity. The improvements in solubility and binding 
suggest that the overall stability of the domain could be improved with only modest 
changes to the overall sequence.  
Most recently, a report by Jacobs et al. describes the use of consensus design to prepare a 
highly stable FN3 domain (Jacobs, et al. 2012). Following an alignment of the 15 FN3 
domains found in the human protein tenascin C or 15 FN3 domains from human 
fibronectin, the researchers designed an alignment based on the most conserved amino acid 
at each position. The resulting consensus domains (Tencon, Tenascin consensus, or Fibcon, 
Fibronectin consensus) demonstrate excellent stability with Tms of 78°C and 90°C 
respectively and adopt the designed fold as confirmed by x-ray crystallography. A series of 
mutations were designed to increase the stability of Tencon even further by consideration of 
core packing and secondary structure preferences for amino acids. Several of the mutations 
which were shown to improve domain stability individually were combined to yield 
scaffold with significantly improved stability and a Tm ~ 93°C. The authors note that 
preliminary data suggests that high affinity, high stability Tencon FN3 domain binders have 
been identified from libraries based on the engineered consensus domain and that the 
improved stability and biophysical properties of library members can be traced to the 
increase stability of the parent scaffold.  
4. Engineering to improve binding affinity 
The compact, simple structure and exceptional stability of the FN3 domain has enabled the 
development of numerous methods for the engineering of high-affinity binders. The 
engineering of an FN3 domain to specifically bind to a non-natural target protein was first 
described by Koide and colleagues, who engineered the FnFN10 to bind specifically to 
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ubiquitin (Koide, et al., 1998). In this seminal paper, the authors introduced random amino 
acids into the BC and FG loops of FN3 and selected binders via phage display. The authors 
chose to randomize these particular loops due to the sequence variations of these loops 
among FN3 family members as well as the fact that FG and/or BC loops have been shown 
to be responsible for interactions with integrins and the human growth hormone receptor 
(de Vos et al., 1992, Main, et al., 1992). One variation found in FN3 structure is the length of 
the loops connecting the -strands. Koide et al. randomized replaced the BC loop with 5 
random amino acids, the same length as that of the native FnFN10, while the randomized 
FG loop was shortened from 8 residues to 5. The resulting library was estimated to be 108 in 
complexity. After selection by phage display, one dominant clone was identified that bound 
specifically to ubiquitin, albeit with low affinity (~ 5 M). Alanine scanning experiments 
demonstrated that residues of both the BC and FG loop contribute to ubiquitin binding.  
A similar FnFN10 phage display library randomizing 5 residues in each of the BC and FG 
loops was displayed on M13 phage, this time with a complexity of 2X109 (Karatan et al., 
2004). After three rounds of selection against the SH3 domain of human c-Src, 6 variants 
were found that bound to the target specifically, with affinities ranging from 0.25 to 1.3 M. 
Most of the clones discovered contained proline rich loops, reminiscent of the binding of 
natural proteins to SH3 domains (Olson, et al., 2008). As with the previous example, both 
the BC and FG loops were found to contribute to SH3 binding. 
A more complex library consisting of a mixture of three separately made libraries in which 
the FG loop, the BC and FG loops, and the BC, FG, and DE loops were randomized was 
produced for selection using the mRNA display system (Dineen et al., 2008, Xu, et al., 2002). 
This library design randomized 21 FN3 residues simultaneously, 10 residues from the FG 
loop, 7 residues from the BC loop, and 4 residues from the DE loop. Because of the use of an 
in vitro display system, a library of very high complexity (1012) was produced. The 
preselected library was panned against TNF which was coupled to sepharose beads and 
screening for binding completed after 9 and 10 rounds of selection. After 10 rounds, a 
diverse set of TNF binding sequences were identified with KD values ranging from 1-24 
nM. In order to drive the selection process to higher affinity, 4 additional rounds of selection 
were completed either with or without the incorporation of error-prone PCR to increase 
diversity. The tightest binder obtained (KD 20 pM) was found from the selection strategy 
incorporating error-prone PCR, indicating that adding diversity to a pool of enriched 
binders can lead to higher affinity binding. The effect on binding of framework mutations 
outside of the randomized loops that might arise from error-prone mutagenesis was not 
investigated in this study. Interestingly the tightest binding clone found had an FG loop that 
was truncated to 4 residues, highlighting the importance of minimizing entropic factors 
when producing high affinity interactions. 
The same FnFN10 mRNA Display library used to isolate TNF binders was also utilized to 
select FN3 domains that bind to the extracellular domain of VEGFR2 (Getmanova et al., 
2006). After 6 rounds of selection, clones binding to VEGFR2 that could compete with the 
binding of VEGF to this receptor were identified. As the affinities of clones from the original 
rounds of selection showed only modest affinity (~ 10 nM), an affinity maturation strategy 
employing hypermutagenic PCR to randomize the loops of the best binder from round 6 
was employed. Although this technique led to only slight improvements in affinity, 2 
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serendipitous mutations in the N-terminal A-strand were found to improve the binding to 
VEGFR2, leading to a second affinity maturation strategy where the FG loop was further 
diversified in combination with truncation of the N-terminus. This alternative strategy led to 
the discovery of anti-VEGFR2 FN3 molecules with affinity as high as 320 pM. 
The previous examples utilizing mRNA display demonstrate the power of large libraries to 
generate high affinity binding molecules. However, several studies have shown that sub-
nanomolar binding affinities can be obtained even with smaller functional libraries. 
Lipovsek et al. used yeast surface display (Boder & Wittrup, 1997) to select lysozyme 
binders from FnFN10 libraries in which 7 BC loop and 7 FG loop residues were randomized 
simultaneously or individually (Lipovsek, et al., 2007). In this case, triplet codons were used 
to generate DNA diversity, thus incorporating all 20 amino acids and no stop codons into 
the functional library. 1 round of magnetic-activated cell sorting and 3 rounds of 
fluorescence-activated cell sorting were used to select yeast displaying FN3 molecules that 
bound to lysozyme. No enrichment was obtained from a library with only the BC loop 
randomized and specific binders were selected from all other libraries. Affinity maturation 
libraries in which 1 loop of a binder was fixed and the other randomized were produced 
and subjected to 4 more rounds of FACS sorting. FN3 domains binding to lysozyme with 
affinities as high as 350 pM were obtained after maturation. Interestingly, the majority of 
FN3 molecules found after affinity maturation, and all of the tightest binders, were found to 
have conserved cysteine residues in each of the BC and FG loops, which presumably 
stabilize the confirmations of the loops by forming a disulfide bond leading to a decrease in 
the entropic penalty of binding and resulting in higher affinities. Similarly, disulfides bonds 
between CDR1 and CDR3 have been found to stabilize camelid single domain antibodies 
(Dong et al., 2011, Sweeney et al., 2008, Tanha et al., 2001).  
A series of studies from the Wittrup lab investigated the effect of amino acid composition 
and loop length on the ability to select high affinity binders by yeast surface display 
(Hackel, et al., 2010, Hackel et al., 2008b, Hackel & Wittrup, 2010). A library, produced by 
PCR and recombination in yeast, randomized the BC, DE, and FG loops of FnFN10 
simultaneously. Diversity was achieved not only by incorporating random amino acids via 
NNB diversity, but also by varying the loop lengths within the library from 4-7 residues 
(DE), 6-9 residues (BC), and 5-10 residues (FG) (Hackel, et al., 2008b). As this library was 
displayed on yeast and could only be made to a diversity of 2.3X107 clones, additional 
diversity was incorporated between rounds of sorting using error-prone PCR of the loops in 
combination with loop shuffling. 3 rounds of selection against lysozyme followed by 4 
additional rounds with affinity maturation and decreasing concentrations of target protein 
were employed to produce FN3 molecules with binding affinities ranging from 1 uM to 2 
pM. Sequence analysis of the selected clones suggests that both loop shuffling and error-
prone PCR can contribute to increased affinities. Mutagenesis of the highest affinity binder 
indicated that binding is dominated by the BC and FG loop and revealed that framework 
mutations derived from error-prone PCR can have a large effect on affinity. The highest 
affinity binders were all found to have length deviations compared to wild-type FnFN10 in 
at least one of the loops, highlighting the potential benefits of incorporating loop length 
diversity into a library. In support of this idea, loop length diversity was also found to be 
important in selecting FnFN10 variants against MBP, hSUMO4, and ySUMO4 using a 
minimalist library composed of only Tyr and Ser at diversified positions (Koide, et al., 2007). 
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It will be interesting to examine if dominant loop lengths emerge as these libraries are used 
to select binders to additional targets. 
A variation of this yeast display library was produced in which the diversity of certain 
FnFN10 loop positions thought to play a role in protein stability were biased towards that of 
the WT FnFN10 protein in order to maximize the stability and folding of library members 
(Hackel, et al., 2010). Three library compositions were compared, the first in which the BC, 
DE, and FG loops were completely randomized, a second in which certain positions in the 
DE loop were biased towards WT sequences and the remaining loop sequences randomized 
as 50% Ser, 50% Tyr, and finally a third design in which structurally important residues in 
the BC and FG loop were biased towards WT sequences and the diversity of the remaining 
residues was tailored to the diversity found in CDR3 of antibodies (Zemlin et al., 2003). 
Yeast surface display levels of random clones from these libraries confirmed that molecules 
from the 3rd library were generally more stably folded, demonstrating the benefit of 
incorporating WT sequences into certain loop positions. For analysis, these three individual 
libraries were pooled and selections carried out against 7 different targets: human A33, 
mouse A33, epidermal growth factor receptor (EGFR), mouse IgG, human serum albumin, 
Fc receptor IIA and Fc receptor IIIA. After selections by yeast surface display, binders 
were selected against each target, although only one binding sequence was found for several 
of the targets. 90% of the recovered sequences were derived from the 3rd library design 
described above, evidence that the improved stability of this library compared to the others 
leads to easier selection of binders. Due to the complex nature of the designs and the mixing 
of the libraries for selections, it is not possible to determine if the increased binding 
efficiency of this library is due to the stabilizing mutations or to the use of diversity tailored 
to resemble the CDRs of antibodies.  
An alternative approach to achieve high affinity relies not on the design of FN3 libraries, but 
solely on an increase in avidity for target binding (Duan et al., 2007). A FnFN10 variant with 
an enhanced RGD sequence in the FG loop that has improved affinity for v3 integrin (J. 
Richards et al., 2003) was produced as a fusion protein to the COMP assembly domain, 
which forms a pentamer via a five-stranded a-helical bundle (Malashkevich et al., 1996). In 
this construct, the FN3 domain was extended from the COMP domain with a 20 amino acid 
helical linker followed by a 25 residue flexible linker. The majority of the fusion protein 
produced in E. coli was found to be pentameric, however monomers, dimers, trimers, and 
tetramers could also be detected by SDS-PAGE. Biacore analysis demonstrated a > 100-fold 
decrease in koff for the pentameric FN3 form in comparison to the monomeric form, 
indicating an avidity effect in binding.  
The studies reviewed here collectively show that a wide range of FN3 library designs can 
lead to the selection of high-affinity binding molecules. The choice of loops to be 
randomized, amino acid composition of the randomizations, length of randomized loops, 
specific positions randomized within the loop, and choice of affinity maturation strategy can 
all have a large effect on the quality and affinity of binders isolated. It has been 
demonstrated that large in vitro display libraries or comparatively smaller phage display 
and smaller yet yeast surface display libraries can all be utilized effectively. No consensus 
has yet emerged as to which loop design strategy yields the best binders, although current 
studies indicate that the FG and BC loops are most important for target binding, while the 
DE loop may help to stabilize the confirmations of the other loops. Strict comparisons of the 
www.intechopen.com
 
FN3 Domain Engineering 
 
155 
effectiveness of the different library designs described are difficult as the target molecules as 
well as the display systems and selection methods utilized are often different between 
studies. However, the pace of published studies describing the selection of FN3 binding 
reagents has quickened considerably since the first description by Koide et al. We anticipate 
that as more detailed characterizations for FN3 binders are reported, rules governing library 
design for this scaffold class will begin to emerge. 
Targets Display 
System
Library Maturation 
Strategy
Highest 
Affinity
Reference 
Ubiquitin P BC5 + FG5 none ~ 5 M Koide, Bailey et al. 1998 
Src SH3 P BC5 + FG5 none 250 nM Karatan, Merguerian et al. 
2004 
TNF- R BC7 + DE4 + 
FG10 
error prone PCR 20 pM Xu, Aha et al. 2002 
VEGFR2 R BC7 + DE4 + 
FG10 
hypermutagenic 
PCR, N-terminal 
truncation 
320 pM Getmanova, Chen et al. 2006 
MBP, hSUMO4, 
ySUMO4 
P + Y Tyr/Ser BC(6-
10) + DE(4-10) 
+ FG(9-13) 
none 5 nM Koide, Gilbreth et al. 2007 
lysozyme Y BC7, FG7, 
BC7 + FG7 
re-randomize BC 
loop 
350 pM Lipovsek, Lippow et al. 2007 
lysozyme Y BC(6-9) + 
DE(4-7) + 
FG(5-10) 
error prone PCR 
+ loop shuffling 
1.1 pM Hackel, Kapila et al. 2008 
Human A33, 
mouse A33, 
EGFR, mIgG, 
HSA, FcRIIA 
and FcRIIIA. 
Y various loop 
compositions 
error prone PCR 
+ loop shuffling 
250 pM Hackel, Ackerman et al. 
2010 
rabbit IgG, goat 
IgG 
Y various loop 
compositions 
and lengths 
error prone PCR 
+ loop shuffling 
51 pM Hackel and Wittrup 2010 
Abl kinase SH2 
domain 
P none Wojcik, Hantschel et al. 2010 
Phosphorylated 
IB 
R BC7 + FG10 none 18 nM Olson, Liao et al. 2008 
N Protein of 
SARS 
R BC7 + FG10 none 1.7 nM Liao, Olson et al. 2009 
Estrogen 
Receptor  
H FG7, AB7 none not 
reported
Koide, Abbatiello et al. 2002 
Table 1. Selected binders from naïve FN3 libraries. Display systems are abbreviated as P for 
phage display, Y for yeast surface display, R for mRNA display, and H for yeast 2-hybrid. 
Numbers in parenthesis after loop descriptions refer to the length of randomized loops. 
Tyr/Ser refers to a loop composition made entirely of tyrosine and serine amino acids. 
5. Applications 
Over the last decade since the first reports on the utility of FN3 domains as antibody mimics 
or alternative scaffold proteins, this class of proteins has been engineered for a variety of 
applications. Affinities of FN3 binders have now been described with values and specificity 
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similar to those obtained for antibody antigen interactions. The inherent biophysical 
properties of FN3 domains and the development of strategies for stability and affinity 
evolution have extended the utility of the scaffold. On the basis of promising preclinical 
tumor xenograft studies for an anti VEGFR2- FN3 domain (Dineen, et al., 2008), the first 
FN3-based therapeutic has been evaluated in human patients in a Phase 1 study 
(Molckovsky & Siu, 2008, Sweeney, et al., 2008). Initial pharmacokinetic studies for a 
PEGylated anti-VEGFR2 FN3 domain dosed intravenously have demonstrated that the 
scaffold has a terminal half-life of ~69 hours with a maximum tolerated dose of 2 mg/kg 
weekly. No clinically significant immunogenicity was observed and a biomarker for 
VEGFR2 demonstrated target engagement. These studies provide the foundation for 
advancement of additional FN3 domain scaffolds into the clinic.  
One of the many attractive features of FN3 domain scaffolds is the ability to link domains 
with different specificities together to form multi-specific therapeutics. As many 
inflammatory and oncologic diseases have been demonstrated to be dependent on activities 
in multiple pathways, the ability to create multi-specific inhibitors has significant potential 
for biotherapeutics. Emanuel and coworkers recently provided the first report of a bispecific 
FN3-domain inhibitor (Emanuel et al., 2011). Adnectins™ with high affinity to epidermal 
growth factor receptor (EGFR) and insulin-like growth factor-1 receptor (IGF-1R) were 
selected using mRNA display. Given that both receptors mediate proliferative and survival 
cell signaling in cancer, bispecific constructs with Adnectins™ fused in tandem via a flexible 
glycine-serine linker were evaluated in vitro. In in vivo studies, pegylated bispecific 
constructs inhibited growth of EGFR and IGF-1R driven tumor xenografts, induced 
degradation of EGFR and reduced EGFR phosphorylation. These studies demonstrate that 
engineering of multi-specific FN3 domains as anti-tumor agents may have the potential to 
improve efficacy over mono-specific biologic therapies.  
Active sites of proteins are often located at domain interfaces in multi-domain proteins. 
Huang et al. explored the potential to engineer a novel interdomain “active site” by linking 
a low-affinity peptide binding domain (the primary domain) with an unrelated FN3 domain 
(the enhancer domain) and evolving for high affinity, high specificity binding (Huang et al., 
2008). Evolution was initiated from the Erbin PDZ domain that has micromolar affinity for 
the C-termini of p-120-related catenins. An FN3 library was linked to the PDZ domain to 
create a two-domain protein interface not naturally observed. The strategy, termed 
“directed domain interface evolution” was used to select a novel protein that bound to the 
target peptide with an affinity enhancement of nearly 500 fold significantly greater than that 
attainable by evolution of the PDZ domain alone. The x-ray crystal structure showed a 
clamshell structure quite similar to the intended design. The novel “affinity-clamp” protein 
demonstrates the utility of FN3 domains as affinity reagents that may be useful in a variety 
of applications. Huang and Koide (Huang & Koide, 210) demonstrated the utility of the 
affinity-clamp strategy to monitor a peptide biomarker using FRET-optimized fluorescent 
proteins. Fusion of one fluorescent protein to the clamp PDZ domain and a second 
fluorescent protein to the FN3 domain allowed for strong FRET activity for the unbound 
affinity clamp. In the presence of target peptide, the affinity clamp undergoes a significant 
conformational change and a large decrease in FRET. The researchers demonstrated that 
peptide concentration in crude cell lysates could be readily quantified over 3 orders of 
magnitude using FRET measurements thus providing a general strategy for monitoring 
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peptide motifs via such label-free sensors. Olson and coworkers took a similar approach 
using mRNA display to select high-affinity phosphorylation-specific IB-binding FN3 
domains (Olson, et al., 2008). The selected domain specifically recognized endogenous 
phosphorylated IB from mammalian cell extracts. The utililty of such specific reagents for 
monitoring kinase activity was demonstrated by creation of n IB kinase (IKK) FRET 
biosensor. To engineer the biosensor, cyan fluorescent protein (CFP) was fused at one end of 
the FN3 domain and yellow fluorescent protein (YFP) at the other end. The IB peptide 
sequence, an IKK substrate, was inserted between the YFP and the FN3 domain where it is 
readily phosphorylated in the presence of IKK. Binding of the phospho-peptide to the FN3 
domain induces a conformational change bringing the two fluorescent domains close 
enough to enable FRET.  
The absence of disulfide bonds in FN3 domains is an attractive feature that suggests the 
potential for these domains to function intracellularly. Liao and coworkers demonstrated 
this potential with selection of FN3 domains that bind to the nucleocapsid protein (N) from 
several acute respiratory syndrome (SARS) coronavirus (Liao, et al., 2009). The researchers 
demonstrated that intrabodies are well expressed in mammalian cells and that they co-
localize with the N-protein. Most significantly, they were able to demonstrate that selected 
intrabodies inhibited virus replication and that intrabodies binding two unique sites on N-
protein can synergize to inhibit virus replication. This work represents the first 
demonstration of intracellularly functional FN3 domains and provides the framework for 
expanding the utility of FN3 scaffolds beyond extracellular targets. Ishikawa and coworkers 
from the same lab used the selected SARS N-protein binders to prepare nanowire/nanotube 
biosensors (Ishikawa et al., 2009). In2O3 nanowire based biosensors were configured with 
the SARS N-protein FN3 domain binder to enable detection of subnanolar concentrations of 
N-protein in the presence of high concentrations of background protein. The concentration 
dependent binding of N-protein demonstrates the utility of biosensors modified with 
engineered FN3 domains for selective and sensitive detection of biomarker proteins.  
A particularly elegant application of FN3 domain binders as fluorescent biosensors was 
recently reported by Gulyani et al. (Gulyani et al., 2011) A Src-family kinase (SFK) biosensor 
was prepared using a FN3 domain specific for activated SFKs. Binding of the FN3 domain to 
its target was monitored by attachment of a bright, environmentally sensitive fluorescent 
dye to the scaffold protein where target protein binding was shown to increase fluorescence. 
Here again, the lack of disulfide bonds in FN3 domains provides the ability for the biosensor 
to function in living cells where SRC activation dynamics can be monitored. Using 
automated image analysis, the biosensor showed specific activation of SFKs during 
protrusion with a level of activity proportional to the velocity of the extending edge. Such 
studies may be extended to other cellular activities via the combination of high throughput 
FN3 domain selections, intracellular functionality, optimization of fluorescent dye 
attachment and biosensor engineering. 
6. Conclusion 
The applications described above represent an evolving landscape for FN3 scaffold domains 
with strategies designed to take advantage of the novel features of such domains. The 
www.intechopen.com
 
Protein Engineering 
 
158 
advent of multiple display platforms together with the development of strategies for 
improving stability, solubility and affinity of FN3 domain binders has laid the foundation 
for novel applications of the platform. We anticipate that bispecific FN3 domain scaffolds 
will become an important therapeutic modality with the potential for increasing specificity 
and efficacy. In addition, the chemical properties of FN3 domains will likely extend their 
utility to intracellular targets. Increasingly, diagnostics and biosensors based on FN3 
domains are expected to play a role in monitoring biomarkers, intracellular signaling 
networks and providing high sensitivity images of intracellular activities. Finally, we expect 
that the biophysical properties of the FN3 scaffolds will play an important role in novel 
targeting and delivery technologies.  
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